Cargando…

Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial

BACKGROUND: Soil-transmitted helminths (STHs) infect almost 1·5 billion people worldwide. The control of STH infections is based on preventive chemotherapy using either albendazole or mebendazole. Before being widely used, a sufficient body of evidence on efficacy, safety and acceptability is warran...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmeirim, Marta S., Bosch, Felix, Ame, Shaali M., Ali, Said M., Hattendorf, Jan, Keiser, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599302/
https://www.ncbi.nlm.nih.gov/pubmed/33150325
http://dx.doi.org/10.1016/j.eclinm.2020.100556
_version_ 1783602840590090240
author Palmeirim, Marta S.
Bosch, Felix
Ame, Shaali M.
Ali, Said M.
Hattendorf, Jan
Keiser, Jennifer
author_facet Palmeirim, Marta S.
Bosch, Felix
Ame, Shaali M.
Ali, Said M.
Hattendorf, Jan
Keiser, Jennifer
author_sort Palmeirim, Marta S.
collection PubMed
description BACKGROUND: Soil-transmitted helminths (STHs) infect almost 1·5 billion people worldwide. The control of STH infections is based on preventive chemotherapy using either albendazole or mebendazole. Before being widely used, a sufficient body of evidence on efficacy, safety and acceptability is warranted for the new chewable child-friendly formulation of mebendazole that was recently developed. METHODS: We conducted a randomised controlled superiority trial in four primary schools and kindergartens on Pemba Island, Tanzania. We considered eligible children aged 3 to 12 years with a hookworm infection intensity of at least 50 eggs per gram (EPG) of stool and no chronic diseases. Participants were allocated to treatment arms (ratio 1:1) using a computer generated random sequence. Our primary outcome was geometric mean based egg reduction rate (ERR) against hookworm assessed 14–21 days post-treatment. This trial complete and is registered with ClinicalTrials.gov, number NCT03995680 (June 24, 2019). FINDINGS: 397 children were eligible and randomised into the solid (198) or chewable (199) tablet arms, of whom 393 were analysed. We found no significant difference between both formulations in terms of ERR (solid 70·8% versus chewable 68·5%, difference in ERR(geometric mean) 2·3%-points, 95% CI -7·8 to 12·6, p = 0.65) and CR (11·2 versus 12·7%, 95% CI -4·9 to 7·9, p = 0.65) against hookworm infections. Adverse events were mild in both treatment arms. INTERPRETATIONS: Though we could not demonstrate superiority in terms of efficacy of the new formulation, the difference between arms was small and therefore, the chewable formulation could be safely used as an alternative to swallowable tablets, in particular in young children who may have swallowing difficulties. This might help increase compliance and, consequently, enhance the effect of preventive chemotherapy.
format Online
Article
Text
id pubmed-7599302
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75993022020-11-03 Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial Palmeirim, Marta S. Bosch, Felix Ame, Shaali M. Ali, Said M. Hattendorf, Jan Keiser, Jennifer EClinicalMedicine Research Paper BACKGROUND: Soil-transmitted helminths (STHs) infect almost 1·5 billion people worldwide. The control of STH infections is based on preventive chemotherapy using either albendazole or mebendazole. Before being widely used, a sufficient body of evidence on efficacy, safety and acceptability is warranted for the new chewable child-friendly formulation of mebendazole that was recently developed. METHODS: We conducted a randomised controlled superiority trial in four primary schools and kindergartens on Pemba Island, Tanzania. We considered eligible children aged 3 to 12 years with a hookworm infection intensity of at least 50 eggs per gram (EPG) of stool and no chronic diseases. Participants were allocated to treatment arms (ratio 1:1) using a computer generated random sequence. Our primary outcome was geometric mean based egg reduction rate (ERR) against hookworm assessed 14–21 days post-treatment. This trial complete and is registered with ClinicalTrials.gov, number NCT03995680 (June 24, 2019). FINDINGS: 397 children were eligible and randomised into the solid (198) or chewable (199) tablet arms, of whom 393 were analysed. We found no significant difference between both formulations in terms of ERR (solid 70·8% versus chewable 68·5%, difference in ERR(geometric mean) 2·3%-points, 95% CI -7·8 to 12·6, p = 0.65) and CR (11·2 versus 12·7%, 95% CI -4·9 to 7·9, p = 0.65) against hookworm infections. Adverse events were mild in both treatment arms. INTERPRETATIONS: Though we could not demonstrate superiority in terms of efficacy of the new formulation, the difference between arms was small and therefore, the chewable formulation could be safely used as an alternative to swallowable tablets, in particular in young children who may have swallowing difficulties. This might help increase compliance and, consequently, enhance the effect of preventive chemotherapy. Elsevier 2020-09-20 /pmc/articles/PMC7599302/ /pubmed/33150325 http://dx.doi.org/10.1016/j.eclinm.2020.100556 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Palmeirim, Marta S.
Bosch, Felix
Ame, Shaali M.
Ali, Said M.
Hattendorf, Jan
Keiser, Jennifer
Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial
title Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial
title_full Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial
title_fullStr Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial
title_full_unstemmed Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial
title_short Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: An open-label, randomized controlled trial
title_sort efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: an open-label, randomized controlled trial
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599302/
https://www.ncbi.nlm.nih.gov/pubmed/33150325
http://dx.doi.org/10.1016/j.eclinm.2020.100556
work_keys_str_mv AT palmeirimmartas efficacysafetyandacceptabilityofanewchewableformulationversusthesolidtabletofmebendazoleagainsthookworminfectionsinchildrenanopenlabelrandomizedcontrolledtrial
AT boschfelix efficacysafetyandacceptabilityofanewchewableformulationversusthesolidtabletofmebendazoleagainsthookworminfectionsinchildrenanopenlabelrandomizedcontrolledtrial
AT ameshaalim efficacysafetyandacceptabilityofanewchewableformulationversusthesolidtabletofmebendazoleagainsthookworminfectionsinchildrenanopenlabelrandomizedcontrolledtrial
AT alisaidm efficacysafetyandacceptabilityofanewchewableformulationversusthesolidtabletofmebendazoleagainsthookworminfectionsinchildrenanopenlabelrandomizedcontrolledtrial
AT hattendorfjan efficacysafetyandacceptabilityofanewchewableformulationversusthesolidtabletofmebendazoleagainsthookworminfectionsinchildrenanopenlabelrandomizedcontrolledtrial
AT keiserjennifer efficacysafetyandacceptabilityofanewchewableformulationversusthesolidtabletofmebendazoleagainsthookworminfectionsinchildrenanopenlabelrandomizedcontrolledtrial